Should IDT prioritize expanding its custom gene synthesis capacity to reduce turnaround times or invest in developing new CRISPR genome editing tools for higher profit margins?

Introduction

The trade-off we're examining today is whether IDT should prioritize expanding its custom gene synthesis capacity to reduce turnaround times or invest in developing new CRISPR genome editing tools for higher profit margins. This scenario involves balancing immediate operational improvements against long-term product innovation in the biotechnology sector. I'll analyze this trade-off by examining the business context, user impact, technical feasibility, and strategic implications for IDT.

Step 1

Clarifying Questions (3 minutes)

• Context: I'm thinking our current gene synthesis capacity might be a bottleneck. Could you share our current turnaround times and how they compare to industry standards?

Why it matters: Helps quantify the potential impact of capacity expansion Expected answer: Our turnaround times are longer than competitors Impact on approach: Would strengthen the case for capacity expansion if true

• Business Context: Based on our revenue model, I assume custom gene synthesis is a significant portion of our business. What percentage of our revenue comes from this service versus CRISPR tools?

Why it matters: Helps prioritize investment based on revenue impact Expected answer: Gene synthesis is currently the larger revenue stream Impact on approach: Would influence resource allocation between the two options

• User Impact: I'm thinking different customer segments might prioritize turnaround time versus advanced CRISPR tools differently. Can you tell me about our key customer segments and their primary pain points?

Why it matters: Ensures the solution addresses critical user needs Expected answer: Mix of academic, biotech, and pharmaceutical clients with varying priorities Impact on approach: Would help tailor the solution to highest-value segments

• Technical Feasibility: Considering the complexity of CRISPR technology, I'm curious about our current capabilities. Do we have the in-house expertise to develop new CRISPR tools, or would this require significant hiring or partnerships?

Why it matters: Assesses the feasibility and timeline of the CRISPR option Expected answer: Some expertise, but would require additional resources Impact on approach: Would influence the timeline and resource allocation for the CRISPR option

• Resource and Timeline: I'm thinking this decision might be influenced by our current financial position and growth targets. What's our investment capacity for the next 12-24 months, and what are our growth expectations?

Why it matters: Aligns the decision with company's financial strategy Expected answer: Moderate investment capacity with ambitious growth targets Impact on approach: Would help balance short-term improvements with long-term innovation